Dapagliflozin; Saxagliptin Hydrochloride Patent Expiration
Dapagliflozin; Saxagliptin Hydrochloride is Used for the treatment of type 2 diabetes mellitus in patients who have inadequate control with dapagliflozin. It was first introduced by Astrazeneca Ab
Dapagliflozin; Saxagliptin Hydrochloride Patents
Given below is the list of patents protecting Dapagliflozin; Saxagliptin Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Qtern | US6414126 | C-aryl glucoside SGLT2 inhibitors and method |
Oct 04, 2020
(Expired) | Astrazeneca Ab |
| Qtern | US6515117 | C-aryl glucoside SGLT2 inhibitors and method | Oct 04, 2025 | Astrazeneca Ab |
| Qtern | US6936590 | C-aryl glucoside SGLT2 inhibitors and method |
Oct 04, 2020
(Expired) | Astrazeneca Ab |
| Qtern | US7919598 | Crystal structures of SGLT2 inhibitors and processes for preparing same | Dec 16, 2029 | Astrazeneca Ab |
| Qtern | US8221786 | Pharmaceutical formulations containing an SGLT2 inhibitor | Mar 21, 2028 | Astrazeneca Ab |
| Qtern | US8361972 | Pharmaceutical formulations containing an SGLT2 inhibitor | Mar 21, 2028 | Astrazeneca Ab |
| Qtern | US8501698 | Crystal structures of SGLT2 inhibitors and processes for preparing same | Jun 20, 2027 | Astrazeneca Ab |
| Qtern | US8628799 | Coated tablet formulation and method | Jul 13, 2025 | Astrazeneca Ab |
| Qtern | US8716251 | Pharmaceutical formulations containing an SGLT2 inhibitor | Mar 21, 2028 | Astrazeneca Ab |
| Qtern | US9198925 | Pharmaceutical formulations containing an SGLT2 inhibitor |
Oct 04, 2020
(Expired) | Astrazeneca Ab |
| Qtern | USRE44186 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul 31, 2023
(Expired) | Astrazeneca Ab |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳